{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:49:36Z","timestamp":1789778976844,"version":"4.0.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"publisher","award":["464251850"],"award-info":[{"award-number":["464251850"]}],"id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What is the impact of PCOS and the hyperandrogenic (HA) PCOS phenotype on the risk of developing hypertension and dyslipidemia?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>PCOS is an independent risk factor for the development of hypertension and dyslipidemia, with the risk being higher among women with the HA PCOS phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>PCOS is an established risk factor for insulin resistance and the metabolic syndrome. However, prospective data regarding the risk of hypertension and dyslipidemia in population-based cohorts of women with PCOS are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This nationwide multiregister-based cohort study included a total of 297\u00a0215 women with PCOS and matched controls followed for up to 20\u2009years. Data were retrieved from the Swedish Patient Register, the Prescribed Drug Register, the Medical Birth Register, the Cause of Death Register, the Total Population Register, and the Education Register.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Study participants resided in Sweden and were born between 1950 and 1999. The median age at study entry was 28\u2009years. Women with a diagnosis of PCOS, androgen excess, or anovulatory infertility recorded in the Swedish Patient Register between 1 January 1997 and 31 December 2016 constituted the study population (n\u2009=\u200950\u2009969). For each woman with PCOS, five controls matched by birth year and municipality were randomly selected from the Total Population Register (n\u2009=\u2009246\u2009246). The primary outcomes were incident hypertension and dyslipidemia after PCOS diagnosis, defined by International Classification of Diseases-10 codes and\/or filled prescriptions for antihypertensive or lipid-lowering medications, respectively. Women with PCOS were further classified as hyperandrogenic (HA) if they had been diagnosed with androgen excess or had a filled prescription for anti-androgenic drugs in the Prescribed Drug Register; otherwise, they were classified as normoandrogenic (NA). Cox regression analyses were performed, adjusted for birth period, country of birth, and education. Overweight and obesity were accounted for in separate models using either BMI or an obesity ICD-10 diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Women with PCOS had a higher risk of developing hypertension compared with non-PCOS women [adjusted Hazard Ratio (aHR) 2.25 (95% CI: 2.13\u20132.39), adjusted for obesity]. Those with the HA-PCOS phenotype had more than 5-fold increased risk [aHR 5.51 (95% CI: 4.97\u20136.10)]. Similarly, PCOS was associated with a higher risk of dyslipidemia [aHR 3.05 (95% CI: 2.69\u20133.46), adjusted for obesity], and women with the HA phenotype exhibited a more than 7-fold increased risk [aHR 7.82 (95% CI: 6.34\u20139.64)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Inclusion of the most severe cases of PCOS could have led to an overestimation of risk estimates. Information on BMI was only available among parous women. The study comprised mainly women with Nordic origin and should be replicated in cohorts with other ethnicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>Women with PCOS, especially those with the HA phenotype, face a substantially increased long-term risk of hypertension and dyslipidemia, highlighting the need for early cardiovascular risk assessment and preventive strategies in this population. The findings underscore that PCOS is not only a reproductive disorder but also a significant cardiovascular risk factor, warranting tailored prevention and management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>The study was funded by the Family Planning Fund, Uppsala, and the Selanders Fund, Uppsala University (grant number 464251850). Furthermore, E.E. has a part-time research position funded by Uppsala University Hospital (grant number ALF 937815). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. E.E. has received lecture fees from Merck AB, none in any way related to this manuscript. The rest of the authors declare no conflicts of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>n\/a.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deag064","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:43:37Z","timestamp":1775043817000},"page":"1197-1206","source":"Crossref","is-referenced-by-count":4,"title":["Hypertension and dyslipidemia in women with PCOS: a population-based multiregister study in Sweden"],"prefix":"10.1093","volume":"41","author":[{"given":"S","family":"Persson","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Turkmen","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Obstetrics and Gynecology, Sundsvall Research Unit, Ume\u00e5 University , Ume\u00e5,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Lind\u00e9n","family":"Hirschberg","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Sundstr\u00f6m Poromaa","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-4682","authenticated-orcid":false,"given":"E","family":"Elenis","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University , Uppsala,","place":["Sweden"]},{"name":"Reproduction Centre, Women\u2019s Clinic, Uppsala University Hospital , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026070609551203800_deag064-B1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2004-1045","article-title":"Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome","volume":"90","author":"Apridonidze","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070609551203800_deag064-B2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/ijerph21030354","article-title":"Prevalence and diagnosis of PCOS using electronic health records: a scoping review and a database analysis","volume":"21","author":"Atiomo","year":"2024","journal-title":"IJERPH"},{"key":"2026070609551203800_deag064-B3","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070609551203800_deag064-B4","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1093\/humrep\/dez185","article-title":"Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource","volume":"34","author":"Azziz","year":"2019","journal-title":"Hum Reprod"},{"key":"2026070609551203800_deag064-B5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jc.2003-031122","article-title":"Androgen excess in women: experience with over 1000 consecutive patients","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070609551203800_deag064-B6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/humupd\/dmw025","article-title":"The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance","volume":"22","author":"Balen","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2026070609551203800_deag064-B7","doi-asserted-by":"crossref","first-page":"100123","DOI":"10.1016\/j.metop.2021.100123","article-title":"PCOS and nutritional approaches: differences between lean and obese phenotype","volume":"12","author":"Barrea","year":"2021","journal-title":"Metabol Open"},{"key":"2026070609551203800_deag064-B8","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"key":"2026070609551203800_deag064-B9","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"2026070609551203800_deag064-B10","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000003072","article-title":"ACOG Practice Bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions","volume":"133","author":"Bulletin","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2026070609551203800_deag064-B11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2005-1457","article-title":"Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism","volume":"91","author":"Carmina","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070609551203800_deag064-B12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fendo.2013.00037","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026070609551203800_deag064-B13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/140349489001800209","article-title":"A quality study of a medical birth registry","volume":"18","author":"Cnattingius","year":"1990","journal-title":"Scand J Soc Med"},{"key":"2026070609551203800_deag064-B14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41371-021-00576-7","article-title":"Sex steroids receptors, hypertension, and vascular ageing","volume":"36","author":"Connelly","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2026070609551203800_deag064-B15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.fertnstert.2018.08.021","article-title":"Beyond fertility: polycystic ovary syndrome and long-term health","volume":"110","author":"Cooney","year":"2018","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.fertnstert.2014.08.001","article-title":"Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?","volume":"102","author":"Daan","year":"2014","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tem.2007.07.004","article-title":"Pathophysiology and types of dyslipidemia in PCOS","volume":"18","author":"Diamanti-Kandarakis","year":"2007","journal-title":"Trends Endocrinol Metab"},{"key":"2026070609551203800_deag064-B18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/humrep\/16.3.556","article-title":"Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population","volume":"16","author":"Elting","year":"2001","journal-title":"Hum Reprod"},{"key":"2026070609551203800_deag064-B19","first-page":"b5232","article-title":"Endocrine and metabolic characteristics in polycystic ovary syndrome","volume":"63","author":"Glintborg","year":"2016","journal-title":"Dan Med J"},{"key":"2026070609551203800_deag064-B20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-018-0680-5","article-title":"Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome","volume":"17","author":"Glintborg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026070609551203800_deag064-B21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/CLEP.S214909","article-title":"Validity of ICD-10 diagnoses of overweight and obesity in Danish hospitals","volume":"11","author":"Gribsholt","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2026070609551203800_deag064-B22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11906-021-01147-4","article-title":"Combined oral contraceptive pill-induced hypertension and hypertensive disorders of pregnancy: shared mechanisms and clinical similarities","volume":"23","author":"Gunaratne","year":"2021","journal-title":"Curr Hypertens Rep"},{"key":"2026070609551203800_deag064-B23","doi-asserted-by":"crossref","first-page":"892125","DOI":"10.3389\/fendo.2022.892125","article-title":"The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population","volume":"13","author":"Guo","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070609551203800_deag064-B24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1600-0412.2012.01458.x","article-title":"The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism","volume":"91","author":"Holm","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026070609551203800_deag064-B25","author":"K\u00e4ll\u00e9n","year":"2003"},{"key":"2026070609551203800_deag064-B26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cen.14647","article-title":"Natural history of polycystic ovary syndrome: a systematic review of cardiometabolic outcomes from longitudinal cohort studies","volume":"96","author":"Kiconco","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026070609551203800_deag064-B27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/obr.12762","article-title":"Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression","volume":"20","author":"Lim","year":"2019","journal-title":"Obes Rev"},{"key":"2026070609551203800_deag064-B28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tjog.2019.05.003","article-title":"Dyslipidemia involvement in the development of polycystic ovary syndrome","volume":"58","author":"Liu","year":"2019","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2026070609551203800_deag064-B29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.reprotox.2022.04.010","article-title":"DNA methylation in polycystic ovary syndrome: emerging evidence and challenges","volume":"111","author":"Liu","year":"2022","journal-title":"Reprod Toxicol"},{"key":"2026070609551203800_deag064-B30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12020-014-0200-7","article-title":"Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome","volume":"47","author":"Livadas","year":"2014","journal-title":"Endocrine"},{"key":"2026070609551203800_deag064-B31","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.fertnstert.2016.07.1121","article-title":"Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2026070609551203800_deag064-B33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026070609551203800_deag064-B34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2026070609551203800_deag064-B35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1139\/Y08-014","article-title":"Lipid and lipoprotein profile in women with polycystic ovary syndrome","volume":"86","author":"Macut","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"key":"2026070609551203800_deag064-B36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"2026070609551203800_deag064-B37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"2026070609551203800_deag064-B38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/humupd\/dmad015","article-title":"PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis","volume":"29","author":"Mill\u00e1n-de-Meer","year":"2023","journal-title":"Hum Reprod Update"},{"key":"2026070609551203800_deag064-B39","author":"Monash University","year":"2023"},{"key":"2026070609551203800_deag064-B40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/JME-17-0023","article-title":"The association of the lipidomic profile with features of polycystic ovary syndrome","volume":"59","author":"Moran","year":"2017","journal-title":"J Mol Endocrinol"},{"key":"2026070609551203800_deag064-B41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1210\/jc.2018-00570","article-title":"Self-reported polycystic ovary syndrome is associated with hypertension: a Northern Finland Birth Cohort 1966 Study","volume":"104","author":"Ollila","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070609551203800_deag064-B42","doi-asserted-by":"crossref","first-page":"2239934","DOI":"10.1080\/09513590.2023.2239934","article-title":"Metabolic characteristics of obese patients with polycystic ovarian syndrome: a meta-analysis","volume":"39","author":"Pan","year":"2023","journal-title":"Gynecol Endocrinol"},{"key":"2026070609551203800_deag064-B43","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.fertnstert.2021.04.018","article-title":"Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome","volume":"116","author":"Persson","year":"2021","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/07435800.2023.2249087","article-title":"Hyperandrogenism protects against high blood pressure by nongenomic mechanisms and obesity causes hypertension in females with polycystic ovary syndrome","volume":"48","author":"Perusquia","year":"2023","journal-title":"Endocr Res"},{"key":"2026070609551203800_deag064-B45","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.fertnstert.2016.12.017","article-title":"Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life","volume":"107","author":"Pinola","year":"2017","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12905-025-03927-5","article-title":"Polycystic ovary syndrome with stroke, hypertension, and cardiovascular diseases: a systematic review and meta-analysis","volume":"25","author":"Pourahmad","year":"2025","journal-title":"BMC Womens Health"},{"key":"2026070609551203800_deag064-B47","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/jcm13030698","article-title":"Possible effect of polycystic ovary syndrome (PCOS) on cardiovascular disease (CVD): an update","volume":"13","author":"Profili","year":"2024","journal-title":"J Clin Med"},{"key":"2026070609551203800_deag064-B48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam","year":"2004","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"2026070609551203800_deag064-B50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cjco.2023.12.010","article-title":"Increased prevalence of adverse health outcomes across the lifespan in those affected by polycystic ovary syndrome: a Canadian population cohort","volume":"6","author":"Vine","year":"2024","journal-title":"CJC Open"},{"key":"2026070609551203800_deag064-B51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish prescribed drug register\u2014a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026070609551203800_deag064-B52","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/humupd\/dmaa029","article-title":"Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis","volume":"26","author":"Wekker","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2026070609551203800_deag064-B53","first-page":"357","article-title":"Cardiometabolic features of polycystic ovary syndrome: role of androgens","volume":"32","author":"Yanes Cardozo","year":"2017","journal-title":"Physiology (Bethesda)"},{"key":"2026070609551203800_deag064-B54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amepre.2024.10.009","article-title":"Hypertensive blood pressure in adolescent females with polycystic ovary syndrome","volume":"68","author":"Zhang","year":"2025","journal-title":"Am J Prev Med"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/41\/7\/1197\/68275377\/deag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/41\/7\/1197\/68275377\/deag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:55:26Z","timestamp":1783346126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/41\/7\/1197\/8676742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deag064","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,12]]}}}